Form 4: Terns Pharma CEO Burroughs Reports Equity Transactions
Insider Trading Report
Terns Pharmaceuticals CEO Amy L. Burroughs reported the acquisition of new equity awards and the exercise and sale of shares under a pre-arranged 10b5-1 trading plan.
Summary
- Amy L. Burroughs, CEO and Director of Terns Pharmaceuticals, Inc., reported multiple equity transactions.
- On January 14, 2026, she acquired 150,000 Restricted Stock Units (RSUs) at a price of $0.00. These RSUs vest 25% on January 1, 2027, and 1/16th quarterly thereafter, fully vesting by January 1, 2030.
- On January 14, 2026, she also acquired 300,000 stock options with an exercise price of $37.18, expiring on January 13, 2036. These options vest 25% on January 1, 2027, and 1/48th monthly thereafter, fully vesting by January 1, 2030.
- On January 15, 2026, she exercised stock options to acquire a total of 68,749 shares of common stock at an exercise price of $4.64 per share.
- Concurrently on January 15, 2026, she sold a total of 68,749 shares of common stock.
- The sales included 61,228 shares at a weighted average price of $37.0153 and 7,521 shares at a weighted average price of $37.5256.
- All reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on June 30, 2025.
- Following these transactions, Burroughs directly owns 288,976 shares and indirectly owns 8,319 shares through a trust. She also holds 984,700 derivative securities (stock options).
Sentiment
Score: 7
Explanation: The filing indicates a mix of new equity grants (positive for long-term alignment) and sales of shares (common for executive compensation, but reduces direct ownership). The transactions were pre-planned, suggesting no immediate market-moving information. The significant gain from option exercise and sale is positive for the executive, reflecting potential stock appreciation.
Positives
- Grant of 150,000 Restricted Stock Units (RSUs) to the CEO, aligning her interests with long-term shareholder value.
- Grant of 300,000 stock options with a 10-year expiration, providing long-term incentive.
- Exercise of options at a low price ($4.64) and subsequent sale at significantly higher prices ($37.0153 and $37.5256), indicating a substantial gain for the executive.
Negatives
- Sale of 68,749 shares by the CEO, which reduces her direct equity stake in the company.
Future Outlook
This filing primarily details executive equity transactions and does not contain forward-looking statements or guidance regarding the company's operational or financial performance beyond the specified vesting schedules for equity awards.
Industry Context
This filing is specific to an individual executive's equity transactions and does not provide information directly related to broader industry trends or competitive landscape analysis.
Related Party Transactions
- The reported transactions are between the CEO (a related party) and the company's equity, executed under a Rule 10b5-1 plan.
Stakeholder Impact
- Shareholders: The sale of shares by the CEO could be perceived negatively by some, but the pre-planned nature mitigates concerns. The new grants align executive incentives with long-term shareholder value.
- Employees: No direct impact mentioned.
- Customers: No direct impact mentioned.
- Suppliers: No direct impact mentioned.
- Creditors: No direct impact mentioned.
Next Steps
- Continued vesting of 150,000 RSUs, with 25% vesting on January 1, 2027, and quarterly thereafter until January 1, 2030.
- Continued vesting of 300,000 stock options, with 25% vesting on January 1, 2027, and monthly thereafter until January 1, 2030.
- Continued vesting of previously granted stock options, with 25% vesting on January 1, 2026, and monthly thereafter until January 1, 2029.
Key Dates
| Date | Description |
|---|---|
| 2025-01-01 | Vesting Commencement Date for previously granted stock options. |
| 2025-06-30 | Date Rule 10b5-1 trading plan was adopted by Amy L. Burroughs. |
| 2026-01-01 | Vesting Commencement Date for newly granted Restricted Stock Units and Stock Options. |
| 2026-01-14 | Date of acquisition of 150,000 Restricted Stock Units and 300,000 Stock Options. |
| 2026-01-15 | Date of option exercises and subsequent sales of common stock. |
| 2026-01-16 | Date the Form 4 was signed. |
| 2030-01-01 | Expected full vesting date for newly granted Restricted Stock Units and Stock Options. |
| 2035-01-29 | Expiration date for previously granted stock options that were partially exercised. |
| 2036-01-13 | Expiration date for newly granted stock options. |
Recommendation
holdThe filing details routine insider transactions under a pre-arranged 10b5-1 plan, including new equity grants and the exercise and sale of previously vested shares. These transactions do not provide new fundamental information about the company's operational performance or strategic direction. While the executive is monetizing some equity, the simultaneous grant of new long-term incentives suggests continued alignment with the company's future. Therefore, the filing itself does not warrant a change in investment thesis, and a 'hold' recommendation is appropriate based solely on this information.
Keywords
Terns Pharmaceuticals, TERN, Amy L. Burroughs, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, RSU, 10b5-1 Plan, Equity Compensation, CEO, Director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.